US Multiple Sclerosis Market size was valued at USD 13,957.7 million in 2022 and is expected to grow at a 6.2% CAGR from 2023 to 2029. Multiple sclerosis is an immune-related disease affecting the central nervous system. Multiple sclerosis is a chronic demyelinating disease in the central nervous system that may significantly cause disability in adults. The inflammation and scarring of myelin sheaths covering the nerves causes multiple sclerosis. The increasing prevalence of multiple sclerosis has increased the demand for effective diagnosis and treatment of multiple sclerosis in the US. According to National Multiple Sclerosis Society USA, approximately 1 million people are living with Multiple Sclerosis in the United States. Multiple sclerosis prevalence has increased in every region since 2013 .The government is also supporting the treatment of multiple sclerosis by raising funds and creating awareness in the public. The key drivers in the growth of US multiple sclerosis market are increasing focus on research and development in order to develop innovative drugs in the market. The major challenge in this treatment is the unknown etiology of the disease which is expected to hinder the market growth in the forecasted period. However, the growing focus of companies on the pipeline drugs for multiple sclerosis is also boosting the multiple sclerosis market growth in US. Biogen, a leading pharmaceutical company in theUS has been developing orelabrutinib, and currently is in the clinical trial phase 2. Moreover, Novartis has been developing remibrutinib which is also currently in the clinical trial phase 3 for the treatment of multiple sclerosis.

US Multiple Sclerosis Market Key Developments:

In June 2022, Sandoz launched a generic drug named Dimethyl Fumarate Hexal, approved for relapsing-remitting multiple sclerosis treatment for adults.
In March 2021, Jansenn Pharmaceuticals, announced US FDA approval for Ponvory, a oral selective sphingosine-1-phosphate receptor 1 modulator to treat relapsing multiple sclerosis in adults. 
In September 2021, TG therapeutics, announced the submission of Biologics license application to US FDA requesting for the approval of ublituximab.